Our Science

Yulia Nefedova, M.D., Ph.D.

Yulia Nefedova, M.D., Ph.D.

  • Assistant Professor, Tumor Microenvironment and Metastasis
  • 215-495-6952, office
Summary

The Nefedova laboratory is interested in the molecular mechanisms that enable tumor cells to interact with their microenvironment--the conditions in which cancer cells and the surrounding tissues operate. In particular, her focus is on the Notch signaling pathway in multiple myeloma, a cancer that affects 22,000 new patients each year, and kills over 10,000.

Nefedova’s team has demonstrated experimentally how Notch and related proteins can trigger the ability of cancerous myeloma cells to resist chemotherapy. Currently, Nefedova and her colleagues continue to investigate strategies that target myeloma cells to enhance their sensitivity to chemotherapy.

Selected Publications

1 - Ramachandran IR, Martner A, Pisklakova A, Condamine T, Chase T, Vogl T, Roth J, Gabrilovich D, Nefedova Y. Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. J Immunol. 2013 Apr;190(7):3815-3823.  23460744.

2 - Youn JI, Kumar V, Collazo M, Nefedova Y, Condamine T, Cheng P, Villagra A, Antonia S, McCaffrey JC, Fishman M, Sarnaik A, Horna P, Sotomayor E, Gabrilovich DI. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol. 2013 Jan;14(3):211-220.23354483.

3 - Chen F, Pisklakova A, Li M, Baz R, Sullivan DM, Nefedova Y. Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myeloma. Cell Oncol (Dordr). 2011 Dec;34(6):545-551.  21965140.  

4 - Li M, Chen F, Clifton N, Sullivan DM, Dalton WS, Gabrilovich DI, Nefedova Y. Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect. Mol Cancer Ther. 2010 Dec;9(12):3200-3209.  21159606.  

5 - Herber DL, Cao W, Nefedova Y, Novitskiy SV, Nagaraj S, Tyurin VA, Corzo A, Cho HI, Celis E, Lennox B, Knight SC, Padhya T, McCaffrey TV, McCaffrey JC, Antonia S, Fishman M, Ferris RL, Kagan VE, Gabrilovich DI. Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med. 2010 Aug;16(8):880-886. 20622859

6 - Nefedova Y, Gabrilovich D. Mechanisms and clinical prospects of Notch inhibitors in the therapy of hematological malignancies. Drug Resist Updat. 2008 Dec;11(6):210-218.   18951834.  

7 - Nefedova Y, Fishman M, Sherman S, Wang X, Beg A, Gabrilovich D. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res. 2007 Nov;67(22):11021-11028. 18006848.

8 - Nefedova Y, Gabrilovich DI. Targeting of Jak/STAT pathway in antigen presenting cells in cancer. Curr Cancer Drug Targets. 2007 Feb;7(1):71-77. 17305479.

9 - Cheng P, Nefedova Y, Corzo CA, Gabrilovich DI. Regulation of dendritic-cell differentiation by bone marrow stroma via different Notch ligands. Blood. 2007 Jan;109(2):507-515. 16973960.  

10 - Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, Gabrilovich DI. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res. 2005 Oct;65(20):9525-9535. 16230418